Legend Biotech (NASDAQ:LEGN – Get Rating) posted its earnings results on Wednesday. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.33, MarketWatch Earnings reports. Legend Biotech had a negative net margin of 429.40% and a negative return on equity of 131.45%. Shares of NASDAQ LEGN opened at $42.65 […]
Legend Biotech (NASDAQ:LEGN – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday, Zacks.com reports. According to Zacks, “Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. […]
Legend Biotech (NASDAQ:LEGN – Get Rating) and NRx Pharmaceuticals (NASDAQ:NRXP – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends. Volatility & Risk Legend Biotech has a beta of -0.1, […]
Several brokerages have updated their recommendations and price targets on shares of Legend Biotech (NASDAQ: LEGN) in the last few weeks: 5/10/2022 – Legend Biotech was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in […]
Legend Biotech (NASDAQ:LEGN – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and […]